Related Experiment Video

Updated: May 9, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

924

Advances in pharmacotherapy of juvenile idiopathic arthritis

Stephanie K A Wong1, Simone Appenzeller2, Marinka Twilt3

  • 1Section of Rheumatology, Department of Pediatrics, British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada.

Expert Opinion on Pharmacotherapy
|May 1, 2025
PubMed

Insights

New treatments for Juvenile Idiopathic Arthritis (JIA) improve outcomes, with biologics showing promise. Future research will refine personalized JIA treatment algorithms using patient data and AI.

Area of Science:

  • Pediatric Rheumatology
  • Immunology

Background:

  • Juvenile Idiopathic Arthritis (JIA) is a prevalent chronic rheumatic condition in childhood.
  • Advances in therapeutic options have led to improved disease status in many children with JIA.

Purpose of the Study:

  • To review novel treatment strategies for non-systemic JIA in pediatric patients.
  • To summarize evidence on the safety and efficacy of biologic treatments for JIA.

Main Methods:

  • Literature review of recent studies on JIA treatments.
  • Analysis of clinical trial data on pharmacokinetics, immunogenicity, efficacy, and safety of novel therapies.

Main Results:

  • Biologic treatments demonstrate significant safety and efficacy in managing JIA.
  • Current treatment advancements are shifting the focus towards achieving remission in JIA patients.

Conclusions:

  • Personalized treatment algorithms for JIA are evolving, with remission as a key goal.
  • Future research should integrate patient preferences, biomarkers, and AI for optimized JIA management.
Abstract

Keywords:
BiologicsDMARDsjuvenile idiopathic arthritispediatric rheumatologytreatment

More Related Videos

Author Spotlight: Assessing Intrathecal Gene Therapy Efficacy in Juvenile Rats04:38

Author Spotlight: Assessing Intrathecal Gene Therapy Efficacy in Juvenile Rats

Published on: March 29, 2024

911
Characterization of Intra-Cartilage Transport Properties of Cationic Peptide Carriers09:02

Characterization of Intra-Cartilage Transport Properties of Cationic Peptide Carriers

Published on: August 10, 2020

7.4K

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
79
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
100
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
86
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
28
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
377